Top of page

Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Insulet $500 million stock offering
Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of Insulet Corporation. The offering resulted in approximately $500…
Alector $150 million at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …
AtriCure $201.2 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC-registered follow-on offering of 4,573,863 shares of common stock…
DexCom $1.05 billion convertible notes offering
Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $1.05 billion aggregate principal amount of its 0.250%…
Affimed $50 million at-the-market offering program
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $50 million gross sales price of…
Zoetis $1.25 billion senior notes offering
Davis Polk advised the joint book-running managers, in connection with an SEC-registered offering by Zoetis Inc. of $750 million aggregate principal amount of its 2.000% senior notes due…
Ayala Pharmaceuticals $55 million IPO
Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…
Anthem $2.5 billion senior notes offering
Davis Polk advised the representatives of the several underwriters on an SEC-registered offering by Anthem, Inc. of $2.5 billion in aggregate principal amount of senior notes, consisting of…
Eli Lilly $1 billion notes offering
Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.0 billion aggregate principal amount of its 2.250% notes due 2050…
Back to top